COMMUNIQUÉS West-GlobeNewswire

XBiotech annonce un accord avec le Cedars-Sinai Medical Center pour évaluer MABp1 en association avec Onivyde® et 5-fluorouracile / acide folinique pour le traitement du cancer du pancréas

22/09/2017 - 00:16

AUSTIN, Texas, le 22 septembre 2017 (GLOBE NEWSWIRE). - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui son accord avec le Cedars-Sinai Medical Center situé à Los Angeles, en Californie, selon lequel XBiotech [...]

Galapagos increases share capital through warrant exercises

21/09/2017 - 22:00

Mechelen, Belgium; 21 September 2017, 22.00 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 28,100 new ordinary [...]

CROSSJECT : Résultats du 1er semestre 2017 et point sur l'activité

21/09/2017 - 18:23

Résultats du 1 er semestre 2017 et point sur l'activité Montée en puissance de l'outil industriel en cours : avec quelques ajustements pour sécuriser la conformité GMP Impacts sur le calendrier prévisionnel : report de [...]

Summit Therapeutics plc : Holding(s) in Company

21/09/2017 - 17:00

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : SUMMIT THERAPEUTICS [...]

Medtronic Announces Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) PRO System in 'Everyday' Clinical Practice

21/09/2017 - 15:30

New Study Designed to Assess Longer-Term Clinical Performance of Next-Generation Evolut PRO Transcatheter Aortic Valve Implantation (TAVI) System DUBLIN - September 21, 2017 - Medtronic plc (NYSE: MDT) today announced a [...]

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference

21/09/2017 - 14:00

AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the [...]

ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare

21/09/2017 - 13:39

ProMIS TM Neurosciences, Inc. NEWS RELEASE TSX: PMN TORONTO, ONTARIO and CAMBRIDGE, MA - September 21, 2017 - ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for [...]

Xbrane Biopharma AB: Xbrane attends Carnegie Nordic HealthCare Day in New York, 5 December

21/09/2017 - 12:13

Press release 2017-09-21 Xbrane is pleased to announce its participation in Carnegie Nordic Healthcare Day in New York in collaboration with the Trout Group, 5 December. The event is for institutional investors and is [...]

Bavarian Nordic Provides Update on its Universal RSV Vaccine

21/09/2017 - 10:13

Preliminary 6 Month Phase 2 Data continue to Demonstrate a Broad and Durable Immune Response against RSV Updated Clinical Plans to Develop and Initiate a Human Challenge Study in 2018 COPENHAGEN, Denmark, September 21, [...]

Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine

21/09/2017 - 10:00

Kymab and Seattle Children's Research Institute publish impressive results using Kymab's KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine KY1005 in combination with [...]

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US

21/09/2017 - 08:00

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company [...]

Nicox signe un accord de licence avec Eyevance pour la commercialisation de ZERVIATE aux Etats-Unis.

21/09/2017 - 07:30

Communiqué de presse Nicox signe un accord de licence avec Eyevance pour la commercialisation de ZERVIATE TM aux Etats-Unis. Nicox recevra 6 millions de dollars à la signature, jusqu'à 42,5 millions de dollars de [...]

Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATETM in the United States

21/09/2017 - 07:30

Press Release Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATE TM in the United States Nicox to receive $6 million upfront payment and up to an additional $42.5 million in future [...]

Mithra Pharmaceuticals: MITHRA ANNOUNCES 2017 HALF YEAR RESULTS

21/09/2017 - 07:30

Regulated information MIThRA ANNOUNCES 2017 HALF YEAR RESULTS Liège, Belgium, 21 September 2017 - Mithra (Euronext Brussels: MITRA), a company specialized in women's health, today announces its financial results for the [...]

Biocartis Group NV: Disclosure of a transparency notification

21/09/2017 - 07:00

PRESS RELEASE: REGULATED INFORMATION 21 September 2017, 07:00 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]

La fondation Dangote et GBCHealth unissent leurs forces pour construire une coalition autour de la santé

21/09/2017 - 04:20

NEW YORK, le 21 septembre 2017 (GLOBE NEWSWIRE) - La fondation Dangote ( www.Dangote.com ) et GBCHealth ont uni leurs forces pour donner naissance à un nouveau modèle de partenariat, l'African Business Coalition on [...]

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure

21/09/2017 - 00:23

DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug [...]

ProtectMyPeople - A New Group Life Insurance Comparison Site - Launches for UK Small and Medium Business Owners

20/09/2017 - 18:48

Price comparison experts, the idol.com have launched the UK's first ever price comparison site for "Death in Service" insurance ProtectMyPeople aims to make group employee benefits more accessible for business owners. [...]

GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2)

20/09/2017 - 18:24

GENFIT : Risque de confusion entre elafibranor, candidat médicament de type PPAR alpha/delta (Phase 3), et lanifibranor, composé de type PPAR a/d/gamma (Phase 2) Alerte initiale sur un risque potentiel d'erreur médicale [...]